Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Therapeutic Antibodies
This essential work, edited by two researchers at London’s famous Queen Mary’s medical school targets one of the most important areas in medical development today. These days, antibody therapeutics are the treatment of choice for several autoimmune and oncological conditions. They are, indeed, becoming the molecules of choice for further combination therapies and cell engineering. In this timely work, a slew of expert in the field of drug development summarize all the current developments and clinical successes.
Gene Therapy for Autoimmune and Inflammatory Diseases
In this monograph about gene therapy of autoimmune and inflammatory d- orders we have gathered international experts and leaders from different fields to review the state of the art advances on topics ranging from disease entities to vectors and engineered cells. The different approaches described in each chapter take into consideration the biomedical knowledge of these diseases and address the complexities of delivering long-term genetic interventions. Gene therapy also serves as a testing ground for new therapeutic entities and helps provide proof of principle for their potential therapeutic role in animal models of disease. Scaling up from mice to men still remains an important h- dle not...
Modern Therapeutics in Rheumatic Diseases
Leading clinicians and clinical researchers discuss in practical detail the newest treatments used in rheumatic diseases, emphasizing-without neglecting current standard treatments-those experimental therapies now undergoing clinical trials and poised for early introduction into the rheumatology armamentarium. The diseases and therapeutic regimes examined here range from rheumatoid arthritis and its treatment by gene therapy, to osteoarthritis and systemic autoimune diseases. Each chapter is organized so that the busy clinician can quickly obtain all the information needed optimal patient treatment. This includes an analysis of the pathogenic mechanisms that explain the molecular basis of the newer therapeutics, reviews of animal data and the results of clinical trials, and recommendations concerning use, side effects, and precautions.
Cytokines and Colony Stimulating Factors
The immune system is a complex network in which different cell types and soluble factors interact to efficiently eliminate various kinds of microorganisms as well as aberrant cell clones. The roots of immunologic investigations reach far into the past. In 430 BC, Thucydides reported that survivors of the plague did not present a second time with similar symptoms. The first report of a successful immu- therapy was made by Edward Jenner in 1798 who found a protective effect of cowpox vaccination against human pox. Since then, much knowledge has been accumulated; today, investigations of the molecular mechanisms of immune regulation are of central research interest. The novel insights into gene...
Intermolecular Cross-talk in Tumor Metastasis
Metastasis of tumours is a sequence of events taking place after the appearance of a primary tumour. The potency of a tumour to metastasise greatly depends on the molecular interactions between tumour components (cellular differentiation and heterogeneity, surface antigenic determinants etc.) and the micro-environment. The complexity and diversity in the composition of tissue micro-environment is in great extent determining the metastatic behaviour or a primary tumour. Extracellular matrix composition, rearrangement of cytoskeleton, cell antigenicity , expression of metastasis-related novel genes, cell adhesion and novel therapeutical approaches such as blockage of angiogenesis, are the major topics discussed in detail in this volume.
Fusion Protein Technologies for Biopharmaceuticals
The state of the art in biopharmaceutical FUSION PROTEIN DESIGN Fusion proteins belong to the most lucrative biotech drugs—with Enbrel® being one of the best-selling biologics worldwide. Enbrel® represents a milestone of modern therapies just as Humulin®, the first therapeutic recombinant protein for human use, approved by the FDA in 1982 and Orthoclone® the first monoclonal antibody reaching the market in 1986. These first generation molecules were soon followed by a plethora of recombinant copies of natural human proteins, and in 1998, the first de novo designed fusion protein was launched. Fusion Protein Technologies for Biopharmaceuticals examines the state of the art in developing...
